Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 20 min ago
Peer-reviewedCC BY-NC-NDEuropean journal of neurology

Anti‐CD20 Drugs and Natalizumab Confer Equal Protection Against Progression Independent of Relapse Activity (PIRA) in People With Multiple Sclerosis

  • Leonardo Palazzo1
  • Ferdinando Clarelli2
  • Michele Surano1
  • Antonino Giordano1
  • Lucia Moiola1
  • Clinical SanRaf MS Study Group1
  • Maria A. Rocca1
  • Massimo Filippi1
  • Federica Esposito1
  1. 1IRCCS Ospedale San Raffaele
  2. 2IRCCS San Raffaele Scientific Institute
Read full textPDFCite

Related

  1. A 2-year multimodal prospective cohort study to predict sustained progression independent of relapse activity in multiple sclerosis
    Luis Rafael Solís-Tarazona, Salma Reddam, Ana Merchán-Cabanillas +3
    Frontiers in NeurologyPeer-reviewedCC BY 4.0Full textNeurologyCrossrefEurope PMCPMC
  2. Multiple sclerosis relapse following gamma knife radiosurgery for meningioma in a patient treated with natalizumab: case report
    Maryna Turbinska, Nabeela Nathoo, Penelope Smyth
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  3. Digital signatures of fatigue and wearing-off symptoms in patients with multiple sclerosis under natalizumab
    Lars Masanneck, Elaine Trautmann, Judith von Pavel +13
    NeurotherapeuticsPeer-reviewedCC BYFull textNeurologyDOAJ
  4. Amyloid-Independent Elevation of Plasma phosphorylated tau-217 Tracks Neurodegenerative Risk in Tuberous Sclerosis Complex: Implications for mTOR-Targeted Intervention
    J. Baumel, M. Lutz, C. Ding +6
    medRxivPreprintAll rights reservedFull textNeurologymedRxiv
  5. Hormone Replacement Therapy and Disability Progression in Women with Multiple Sclerosis
    T. P. Copeland, K. A. McKay, A. Pedersen +2
    medRxivPreprintAll rights reservedFull textNeurologymedRxiv

Cite

BibTeXRIS
BibTeX
@article{palazzo2026anticd20,
  title = {{Anti‐CD20 Drugs and Natalizumab Confer Equal Protection Against Progression Independent of Relapse Activity (PIRA) in People With Multiple Sclerosis}},
  author = {Leonardo Palazzo and Ferdinando Clarelli and Michele Surano and Antonino Giordano and Lucia Moiola and Clinical SanRaf MS Study Group and Maria A. Rocca and Massimo Filippi and Federica Esposito},
  journal = {European journal of neurology},
  year = {2026},
  month = oct,
  url = {https://europepmc.org/article/PMC/PMC13660713},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Anti‐CD20 Drugs and Natalizumab Confer Equal Protection Against Progression Independent of Relapse Activity (PIRA) in People With Multiple Sclerosis
AU  - Leonardo Palazzo
AU  - Ferdinando Clarelli
AU  - Michele Surano
AU  - Antonino Giordano
AU  - Lucia Moiola
AU  - Clinical SanRaf MS Study Group
AU  - Maria A. Rocca
AU  - Massimo Filippi
AU  - Federica Esposito
PY  - 2026
DA  - 2026/10/01
JO  - European journal of neurology
UR  - https://europepmc.org/article/PMC/PMC13660713
SN  - 1351-5101
SN  - 1468-1331
ER  -